A phase III, open label, randomized, comparative study of the antiviral efficacy of ARV [antiretroviral] therapy with lopinavir/ritonavir (LPV/r-Kaletra) in combination with tenofovir (TDF) versus standard of care (Kaletra in combination with 2 nucleoside RTIs [reverse transcriptase inhibitors]) in naive-HIV-1 positive patients

Trial Profile

A phase III, open label, randomized, comparative study of the antiviral efficacy of ARV [antiretroviral] therapy with lopinavir/ritonavir (LPV/r-Kaletra) in combination with tenofovir (TDF) versus standard of care (Kaletra in combination with 2 nucleoside RTIs [reverse transcriptase inhibitors]) in naive-HIV-1 positive patients

Completed
Phase of Trial: Phase III

Latest Information Update: 13 Jun 2014

At a glance

  • Drugs Lopinavir/ritonavir (Primary) ; Nucleoside reverse transcriptase inhibitors; Tenofovir disoproxil fumarate
  • Indications HIV-1 infections
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms KALEAD
  • Sponsors Abbott Laboratories
  • Most Recent Events

    • 09 Mar 2008 Status changed from in progress to completed, updated from ClinicalTrials.gov.
    • 25 Jul 2007 Interim results have been reported.
    • 25 Jun 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top